Endocrine Abstracts

Background: Cabergoline is effective in achieving normoprolactinaemia and tumour shrinkage in about 70% of patients with macroprolactinoma. Only a few studies have followed-up the adenoma shrinkage for periods >2 years;the need for continuing imaging thereafter is not certain.Aim: To evaluate tumour volume changes in patients with macroprolactinoma responsive to cabergoline during a long follow-up period.Patients and methods: M...

Background: Treatment of patients with acromegaly caused by pituitary adenoma with somatostatin analogues leads to significant tumour shrinkage in 23–73% of the cases. Although not widely accepted, it has been suggested that the surgical remission rate may be improved by pre-operative treatment with these agents.Aim: To assess whether the degree of tumour shrinkage by lanreotide offered pre-operatively affects the surgical success in acromegalics wi...

Introduction: Data on the mortality of patients with non-functioning pituitary macroadenoma (NFA) are limited. Aim: To assess the mortality of patients with NFA and predictive factors.Patients/methods: All patients presenting to our Department with NFA between 1963 and 2011 were studied. Status was recorded as either dead or alive, as of 31 December 2011.Results: 546 patients (333 males) were identified (median age at surgery 58.7 ...

Introduction: Data on the mortality of patients with non-functioning pituitary macroadenoma (NFA) are very limited.Aim: To assess the mortality of patients with NFA and factors predicting it.Patients and methods: All patients presenting to our department with NFA between 1963 and 2011 were studied. Status was recorded as either dead or alive, as of 31st December 2011.Results: 546 patients (333 males) were ide...

Introduction: Despite the significant risk of regrowth of non-functioning pituitary adenomas (NFAs) after primary treatment, systematic data on the probability of further tumour progression and the effectiveness of management approaches are lacking.Aims: Assess the probability of further regrowth(s), predictive factors and outcomes of management approaches in patients with NFA diagnosed with adenoma regrowth after primary treatment (surgery combined or n...